Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

By D. Harper, E. Franco, C. Wheeler, D. Ferris, D. Jenkins, A. Schuind, T. Zahaf, B. Innis, P. Naud, N. D. de Carvalho and 6 more. The Lancet, 2004

1,628 citations recorded by the source corpus.

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

Immune responses to human papillomavirus. (2006, background): “This confirms the results of previous trials showing that HPV 16 or HPV 16/18 vaccines confer protection against cervical intraepithelial neoplasia induced by these respective HPV types [ 61 ,62], and strongly suggests that anogenital disease induced by HPV 6 or 11 can be controlled.”
Baculovirus as versatile vectors for protein expression in insect and mammalian cells (2005, methodology): “VLPs composed of the HPV types 16/18 L1 structural proteins produced in baculovirus-infected insect cells have been shown in clinical trials to be efficacious in preventing cervical infections with HPV-16 and HPV-18, together with the associated cytological abnormalities and lesion”